rilvegostomig — Initial data
2026
Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with 10 ongoing Phase 3 clinical trials, and anticipates further Phase 1/2 clinical trial data with rilvegostomig in 2026Source filing
CGEN biotech catalysts & pipeline
COMPUGEN LTD · Data as of 2026-09-08
Upcoming catalysts
COM701 — Interim data
by Q1 2027
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027Source filing